Your session is about to expire
← Back to Search
Triple-Drug Combo for Liver Cancer (RELATIVITY-106 Trial)
RELATIVITY-106 Trial Summary
This trial will compare the safety and effectiveness of a three-drug combo of nivolumab, relatlimab, and bevacizumab versus a two-drug combo of just nivolumab and bevacizumab in people with HCC that has not yet been treated.
RELATIVITY-106 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRELATIVITY-106 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533RELATIVITY-106 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver function is slightly impaired.I have not had systemic therapy for advanced liver cancer, but prior immunotherapy is okay if my cancer returned 6 months after treatment.I am fully active or can carry out light work.My liver cancer is confirmed to be advanced or has spread.I have had a previous organ or stem cell transplant.My liver cancer is a specific type (fibrolamellar, sarcomatoid, or mixed with bile duct cancer).I have brain metastases that have not been treated and are causing symptoms.I have had or currently have serious fluid buildup in my abdomen needing treatment.
- Group 1: Arm A: Relatlimab + Nivolumab + Bevacizumab
- Group 2: Arm B: Placebo + Nivolumab + Bevacizumab
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the target number of patients for this clinical trial?
"The trial needs 162 patients that satisfy the basic requirements in order to start. The research will be conducted by Bristol-Myers Squibb at various hospitals, with some being Johns Hopkins Medicine - Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland and Local Institution - 0025 in Edmonton, Alberta."
Are we able to enroll new patients in this research project at this time?
"The study is still recruiting patients, as noted on the clinicaltrials.gov website. This particular trial was initially posted on May 5th, 2022 and has since been updated October 17th of the same year."
How many hospitals are participating in this research project?
"There are a total of 17 sites running this study, including Johns Hopkins Medicine - Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, Local Institution - 0025 in Edmonton, Alberta, and California Pacific Hematology Oncology Associates in San Francisco, California."
Share this study with friends
Copy Link
Messenger